Annals of Surgical Oncology

, Volume 23, Issue 1, pp 38–43 | Cite as

Intraoperative Ultrasound-Guided Lumpectomy Versus Mammographic Wire Localization for Breast Cancer Patients After Neoadjuvant Treatment

  • Isabel T. Rubio
  • Antonio Esgueva-Colmenarejo
  • Martin Espinosa-Bravo
  • Juan Pablo Salazar
  • Ignacio Miranda
  • Vicente Peg
Breast Oncology



Intraoperative ultrasound (IOUS)-guided lumpectomy in early breast cancer has shown advantages over other techniques. However, the use of IOUS has been less explored after neoadjuvant treatment (NAT). This study aimed to compare IOUS- and wire localization (WL)-guided surgery in breast cancer patients after NAT.


The study enrolled patients treated with NAT who underwent breast-conserving surgery (BCS) between July 2008 and December 2012. For the patients with a hydrogel marker or residual tumor visible on ultrasound, an IOUS-guided surgery was performed (IOUS group). The patients with a standard marker or hydrogel marker not visible on ultrasound underwent a WL-guided surgery (WL group).


The study investigated 214 patients: 145 (67.8 %) in the IOUS group and 69 (32.2 %) in the WL group. The patient and tumor characteristics were comparable between the two groups. For the patients who had a pathologic complete response (pCR) or microscopic disease, the volume excised was lower in the IOUS group (p = 0.03). The rate of reexcision for positive or close margins was similar in the two groups (p = 0.80). After a median follow-up period of 43 months, the local recurrence rates did not differ significantly between the two groups.


Compared with WL surgery, IOUS seems to lower the volume of resection in patients with pCR or minimal microscopic disease after NAT without compromising margins and local recurrences. BCS can easily be achieved with IOUS for patients with a good response after NAT.


Positive Margin Negative Margin Close Margin Wire Localization Radioactive Seed 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Kaufmann M, von Minckwitz G, Bear H, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. 2007;18:1927–34.PubMedCrossRefGoogle Scholar
  2. 2.
    Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672–85.PubMedGoogle Scholar
  3. 3.
    Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol. 2008;26:778–85.PubMedCrossRefGoogle Scholar
  4. 4.
    van der Hage JA, van de Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European organization for research and treatment of cancer trial 10902. J Clin Oncol. 2001;19:4224–37.PubMedGoogle Scholar
  5. 5.
    Chen A, Meric-Bernstam F, Hunt K, et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol. 2004;22:2303–12.PubMedCrossRefGoogle Scholar
  6. 6.
    Kuerer HM, Hunt KK, Newman LA, Ross MI, Ames FC, Singletary SE. Neoadjuvant chemotherapy in women with invasive breast carcinoma: conceptual basis and fundamental surgical issues. J Am Coll Surg. 2000;190:350–63.PubMedCrossRefGoogle Scholar
  7. 7.
    Bear HD. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B27. J Clin Oncol. 2003;21:4165–74.PubMedCrossRefGoogle Scholar
  8. 8.
    Minckwitz von G, Untch M, Blohmer J-U, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30:1796–804.CrossRefGoogle Scholar
  9. 9.
    Baselga J, Bradbury I, Eidtmann H, NeoALTTO Study Team, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomized, open-label, multicentre, phase 3 trial. Lancet. 2012;379:633–40.PubMedCrossRefGoogle Scholar
  10. 10.
    Donker M, Drukker CA, Valdes Olmos RA, et al. Guiding breast-conserving surgery in patients after neoadjuvant systemic therapy for breast cancer: a comparison of radioactive seed localization with the ROLL technique. Ann Surg Oncol. 2013;20:2569–72.PubMedCrossRefGoogle Scholar
  11. 11.
    Espinosa-Bravo M, Sao Avilés A, Esgueva A, et al. Breast-conservative surgery after neoadjuvant chemotherapy in breast cancer patients: comparison of two tumor localization methods. Eur J Surg Oncol. 2011;37:1038–43.PubMedCrossRefGoogle Scholar
  12. 12.
    Ramos M, Diez JC, Ramos T, Ruano R, Sancho M, Gonzalez-Orus JM. Intraoperative ultrasound in conservative surgery for non palpable breast cancer after neoadjuvant chemotherapy. Int J Surg. 2014;12:572–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Rubio IT, Henry-Tillman R, Klimberg VS. Surgical use of breast ultrasound. Surg Clin North Am. 2003;83:771–88.PubMedCrossRefGoogle Scholar
  14. 14.
    Krekel NMA, Zonderhuis BM, Stockmann HBAC, et al. A comparison of three methods for nonpalpable breast cancer excision. Eur J Surg Oncol. 2011;37:109–15.PubMedCrossRefGoogle Scholar
  15. 15.
    Cox CE, Furman B, Stowell N, et al. Radioactive seed localization breast biopsy and lumpectomy: can specimen radiograph be eliminated? Ann Surg Oncol. 2004;10:1039–47.CrossRefGoogle Scholar
  16. 16.
    Sung JS, King V, Thornton CM, et al. Safety and efficacy of radioactive seed localization with I-125 prior to lumpectomy and/or excisional biopsy. Eur J Radiol. 2013;82:1453–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Thind CR, Tan S, Desmond S, et al. SNOLL: sentinel node and occult (impalpable) lesion localization in breast cancer. Clin Radiol. 2011;66:833–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Lovrics PJ, Goldsmith CH, Hodgson N, et al. A multicenter randomized controlled trial comparing radio-guided seed localization to standard wire localization for nonpalpable, invasive, and in situ breast carcinoma. Ann Surg Oncol. 2011;18:3407–14.PubMedCrossRefGoogle Scholar
  19. 19.
    Thompson M, Klimberg VS. Use of breast ultrasound in surgery. Surg Clin North Am. 2007;87:469–84.PubMedCrossRefGoogle Scholar
  20. 20.
    Smith LF, Rubio IT, Henry-Tillman R, et al. Intraoperative ultrasound-guided breast biopsy. Am J Surg. 2000;180:419–23.PubMedCrossRefGoogle Scholar
  21. 21.
    Rahusen FD, Bremers AJA, Fabry HFJ, et al. Ultrasound-guided lumpectomy of nonpalpable breast cancer versus wire-guided resection: a randomized clinical trial. Ann Surg Oncol. 2002;9:994–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Moore MM, Whitney LA, Cerilli L, Imbrie JZ, Bunch M, Simpson VB, Hanks JB. Intraoperative ultrasound is associated with clear lumpectomy margins for palpable infiltrating ductal breast cancer. Ann Surg. 2001;233:761–8.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Ahmed M, Douek M. Intraoperative ultrasound versus wire-localization in the surgical management of non palpable breast cancers: systematic review and meta-analysis. Breast Cancer Res Treat. 2013;140:435–46.PubMedCrossRefGoogle Scholar
  24. 24.
    Blumencranz PW, Ellis D, Barlowe K. Use of hydrogel breast biopsy tissue markers reduces the need for wire localization. Ann Surg Oncol. 2014;21:3272–7.CrossRefGoogle Scholar
  25. 25.
    Van Riet YE, Maaskant AJ, Creemers GJ, et al. Identification of residual breast tumor localization after neoadjuvant chemotherapy using a radioactive 125 iodine seed. Eur J Surg Oncol. 2010;36:164–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Gobardhan PD, de Wall LL, van der Laan L, et al. The role of radioactive iodine-125 seed localization in breast-conserving therapy following neoadjuvant chemotherapy. Ann Oncol. 2012;24:668–73.PubMedCrossRefGoogle Scholar
  27. 27.
    Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guidelines (version 1.1). Eur J Cancer. 2009;45:228–47.PubMedCrossRefGoogle Scholar
  28. 28.
    Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, Schofield A, Heys SD. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12:320–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Boughey JC, Peintinger F, Meric-Bernstam F, et al. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg. 2006;244:464–70.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Criscitiello C, Azim HA Jr, Agbor-Tarh D, et al. Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. Ann Oncol. 2013;24:1980–5.PubMedCrossRefGoogle Scholar
  31. 31.
    Debled M, MacGrogan G, Breton-Callu C, et al. Surgery following neoadjuvant chemotherapy for HER2-positive locally advanced breast cancer: time to reconsider the standard attitude. Eur J Cancer. 2015;51:697–704.PubMedCrossRefGoogle Scholar
  32. 32.
    Kass R, Kumar G, Klimber VS, et al. Clip migration in stereotactic biopsy. Am J Surg. 2002;184:325–31.PubMedCrossRefGoogle Scholar
  33. 33.
    Krekel NM, Lopes Cardozo AM, Muller S, et al. Optimizing surgical accuracy in palpable breast cancer with intra operative breast ultrasound-feasibility and surgeon’s learning curve. Eur J Surg Oncol. 2011;37:1044–50.PubMedCrossRefGoogle Scholar
  34. 34.
    Wazer DE, DiPetrillo T, Schmidt-Ullrich R, et al. Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol. 1992;10:356–63.PubMedGoogle Scholar
  35. 35.
    Krekel N, Zonderhuis B, Schreurs H, et al. Ultrasound-guided breast-sparing surgery to improve cosmetic outcomes and quality of life: a prospective multicentre randomized controlled clinical trial comparing ultrasound-guided surgery to traditional palpation-guided surgery (COBALT trial). BMC Surg. 2011;11:8.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Cochrane RA, Valasiadou P, Wilson AR, et al. Cosmesis and satisfaction after breast-conserving surgery correlates with the percentage of breast volume excised. Br J Surg. 2003;90:1505–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology–American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Ann Surg Oncol. 2014;21:704–16.PubMedCrossRefGoogle Scholar
  38. 38.
    Truin W, Vugts G, Roumen RM, et al. Differences in response and surgical management with neoadjuvant chemotherapy in invasive lobular versus ductal breast cancer. Ann Surg Oncol. 2015. Epub ahead of print.Google Scholar

Copyright information

© Society of Surgical Oncology 2015

Authors and Affiliations

  • Isabel T. Rubio
    • 1
  • Antonio Esgueva-Colmenarejo
    • 1
  • Martin Espinosa-Bravo
    • 1
  • Juan Pablo Salazar
    • 2
  • Ignacio Miranda
    • 2
  • Vicente Peg
    • 3
  1. 1.Breast Surgical Oncology UnitHospital Universitario Vall d’HebronBarcelonaSpain
  2. 2.Department of RadiologyHospital Universitario Vall d’HebronBarcelonaSpain
  3. 3.Department of PathologyHospital Universitario Vall d’HebronBarcelonaSpain

Personalised recommendations